MAP kinase signalling pathways in cancer
Top Cited Papers
Open Access
- 14 May 2007
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 26 (22), 3279-3290
- https://doi.org/10.1038/sj.onc.1210421
Abstract
Cancer can be perceived as a disease of communication between and within cells. The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently. Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer. Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway. Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation. The balance and integration between these signals may widely vary in different tumours, but are important for the outcome and the sensitivity to drug therapy.Keywords
This publication has 140 references indexed in Scilit:
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- Raf Kinase Inhibitory Protein Regulates Aurora B Kinase and the Spindle CheckpointMolecular Cell, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- RAS and RHO GTPases in G1-phase cell-cycle regulationNature Reviews Molecular Cell Biology, 2004
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinomaCancer, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- The Hallmarks of CancerCell, 2000